Human Medicines Highlights March 2026

6th March 2026

Latest edition of the Human Medicines Highlights newsletter from EMA is out now.

Featuring:

• EMA’s human medicines committee (CHMP) recommendations for granting marketing authorisations

• EMA  launched a recruitment process for its next Executive Director

• EMA’s safety committee (PRAC) recommended withdrawal of marketing authorisations for levamisole medicines, which are used to treat parasitic worm infections.

• Information about the latest episode of our ‘Inside EMA’ podcast

• And more.

View here.

Back to Recent News